Replies to post #1383 on Vascular Biogenics Ltd (VBLT)

[gr8db8]

Trial will be stopped if mOS improved by 50%+. Optune's trial was stopped with less significant improvement in mOS:

In the per-protocol population, patients treated with TTFields plus temozolomide demonstrated a statistically significant increase in OS, a powered secondary endpoint, compared to temozolomide alone (median OS 20.5 months versus 15.6 months, hazard ratio=0.64, p=0.0042). In the intent-to-treat population, the median OS was 19.6 months versus 16.6 months, respectively, hazard ratio=0.74 (p=0.0329).

http://www.businesswire.com/news/home/20151215005370/en/Journal-American-Medical-Association-JAMA-Publishes-Pivotal

[Jumpinjackas]

If it's that easy then why the market cap doesn't reflect that?
Remember, there are more powerful investors with much more resources out there.

It's odd that we have no DSMC news yet. I'm hoping that it is being delayed due to request for more analysis...to halt sure to efficacy... Very unlikely, but possible

[Oren1976]

May I ask what "ca" stands for in ur messages ?